Nonsteroidal anti-inflammatory drug hypersensitivity: Fable or reality?

European Journal of Dermatology

Volumn 15, Issue 3, 2005, Pages 164-167

  Schubert, Barbara ^a   Grosse Perdekamp, Maria T ^b   Pfeuffer, Petra ^a   Raith, Petra ^a   Bröcker, Eva B ^a   Trautmann, Axel ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Cancer Care Specialists of Central Illinois   (United States)

Author keywords

Drug challenge; Drug provocation; Nonallergic hypersensitivity; Nonsteroidal anti inflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CELECOXIB; DICLOFENAC; GLUCOCORTICOID; IBUPROFEN; IMMUNOGLOBULIN E; INDOMETACIN; MEFENAMIC ACID; NEFOPAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PLACEBO; ROFECOXIB;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; ATOPIC DERMATITIS; AWARENESS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RESPIRATORY TRACT DISEASE; RHINITIS; SAFETY; SCHOOL CHILD; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN TEST; URTICARIA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PATCH TESTS; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SINGLE-BLIND METHOD; SKIN;

EID: 19544371592     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-21.
2. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001; 87: 177-80.
3. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs. Clin Rev Allergy Immunol 2003; 24: 125-36.
4. Fahrenholz JM. Natural history and clinical features of aspirin-exocerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24: 113-24.
5. Settipane GA. Aspirin and allergic diseases: a review. Am J Med 1983; 74: 102-9.
6. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol 2002; 3: 599-607.
7. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57: 569-74.
8. Falliers CJ. Aspirin and subtypes of asthma: risk factor analysis. J Allergy Clin Immunol 1973; 52: 141-7.
9. Bochenek G, Nizankowska E, Szczeklik A. The atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 1996; 51: 16-23.
10. Sanchez-Borges M, Capriles-Huleft A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol 2000; 84: 101-6.
11. Johansson SGO, Hourihane JOB, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task Force. Allergy 2001; 56: 813-24.
12. Bircher AJ. Drug-induced urticoria and ongioedema caused by non-IgE mediated pathomechanisms. Eur J Dermatol 1999; 9: 657-63.
13. Cousin F, Philips K, Fovier B, Bienvenu J, Nicolas JF. Drug-induced urticaria. Eur J Dermatol 2001; 11: 181-7.
14. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3: 588-93.
15. Stevenson DD. Challenge procedures in detection of reactions to aspirin and nonsteroidol anti-inflammatory drugs. Ann Allergy 1993; 71: 417-8.
16. Brockow K, Romano A, Bianca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
17. Zuberbier T. Urticaria. Allergy 2003; 58: 1224-34.
18. Aoki T, Kojima M, Horiko T. Acute urticaria: history and natural course of 50 cases. J Dermatol 1994; 21: 73-7.
19. Berthelot JM, Maugors Y, Abgrall M, Prost A. Interindividual variations in beliefs about the placebo effect: a study in 300 rheumatology inpatients and 100 nurses. Joint Bone Spine 2001; 68: 65-70.
20. Shepherd M. The placebo: from specificity to the non-specific and back. Psychol Med 1993; 23: 569-78.
21. Clark PI, Leaverton PE. Scientific and ethical issues in the use of placebo controls in clinical trials. Annu Rev Public Health 1994; 15: 19-38.
22. Kienle GS, Kiene H. Placebo effect and placebo concept: a critical methodological and conceptual analysis of reports on the magnitude of the placebo effect. Altern Ther Health Med 1996; 2: 39-54.
23. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287: 622-7.
24. Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med 1999; 130: 910-21.
25. Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004; 140: 1001-6.
26. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy 2002; 57: 37-40.
27. Probst L, Stoney P, Jeney E, Hawke M. Nasal polyps, bronchial asthma and aspirin sensitivity. J Otolaryngol 1992; 21: 60-5.
28. Quiralte J, Saenz de San PB, Florida JJ. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002; 89: 63-6.
29. Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D, et al. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 2003; 132: 82-6.
30. Asero R. Tolerability of rofecoxib. Allergy 2001; 56: 916-7.
31. Matucci A, Parronchi P, Vultaggio A, Rossi O, Brugnolo F, Maggi E, et al. Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy 2004; 59: 1133-4.
32. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fanseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001; 87: 201-4.
33. Passalacqua G, Milanese M, Mincarini M, Ciprandi G, Guerra L, Scordamaglia A, et al. Single-dose oral tolerance test with alternative compounds for the management of adverse reactions to drugs. Int Arch Allergy Immunol 2002; 129: 242-7.